Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

81. Monarch external Trigeminal Nerve Stimulation System for drug-refractory epilepsy

Monarch external Trigeminal Nerve Stimulation System for drug-refractory epilepsy HealthPACT Health Policy Advisory Committee on Technology Australia and New Zealand Technology Brief 90Y Zevalin for the treatment of non-Hodgkin’s lymphoma (v1.0) August 2011 © State of Queensland (Queensland Health) 2011 This work is licensed under a Creative Commons Attribution Non-Commercial No Derivatives 2.5 Australia licence. In essence, you are free to copy and communicate the work in its current form

2018 COAG Health Council - Horizon Scanning Technology Briefs

82. Neuropsychological outcome after subtemporal versus transsylvian approach for selective amygdalohippocampectomy in patients with mesial temporal lobe epilepsy: a randomised prospective clinical trial

Neuropsychological outcome after subtemporal versus transsylvian approach for selective amygdalohippocampectomy in patients with mesial temporal lobe epilepsy: a randomised prospective clinical trial To compare the effects of different surgical approaches for selective amygdalohippocampectomy in patients with pharmacoresistant mesial temporal lobe epilepsy with regard to the neuropsychological outcome and to replicate an earlier study employing a matched-pair design.47 patients were randomised (...) to subtemporal versus transsylvian approaches. Memory, language, attentional and executive functions were assessed before and 1 year after surgery. Multivariate analyses of variance (MANOVAs) with presurgical and postsurgical assessments as within-subject variables and approach and side of surgery as between-subject factors were calculated. Additionally, the frequencies of individual performance changes based on reliable change indices were analysed.Seizure freedom International League Against Epilepsy (ILAE

2018 EvidenceUpdates

83. Losigamone add-on therapy for focal epilepsy. (PubMed)

Losigamone add-on therapy for focal epilepsy. Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and they usually require treatment with a combination of two or more AEDs. In recent years, many newer AEDs have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review (...) . This is an update of a Cochrane review first published in 2012 (Cochrane Database of Systematic Reviews 2012, Issue 6) and updated in 2015.To investigate the efficacy and safety of losigamone when used as an add-on therapy for focal epilepsy.For the latest update on 9 February 2017, we searched the Cochrane Epilepsy Specialized Register, CENTRAL and MEDLINE . We searched trials registers and contacted the manufacturer of losigamone and authors of included studies for additional information. We did not impose

2018 Cochrane

84. Management of epilepsy in adults with intellectual disability

Management of epilepsy in adults with intellectual disability Management of epilepsy in adults with intellectual disability (CR203 May 2017) This site uses cookies: Search Search Become a psychiatrist Choose psychiatry Medical students Foundation doctors Help us promote psychiatry Training Curricula and guidance Your training Exams Neuroscience in training International Medical Graduates Members Supporting you Submitting your CPD Membership Your Faculties Devolved Nations English Divisions (...) International members Special Interest Groups Your monthly eNewsletter Specialty doctors President's lectures Events Conferences and training events In house training International Congress Improving care CCQI Campaigning for better mental health policy Planning the psychiatric workforce National Collaborating Centre for Mental Health Working sustainably Mental health Problems and disorders Support, care and treatment Translations Management of epilepsy in adults with intellectual disability (CR203 May 2017

2018 Royal College of Psychiatrists

85. Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability

Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability (CR206 Oct 2017) This site uses cookies: Search Search Become a psychiatrist Choose psychiatry Medical students Foundation doctors Help us promote psychiatry Training Curricula and guidance Your training Exams Neuroscience in training International Medical Graduates Members Supporting you Submitting your CPD Membership Your (...) drugs for people with epilepsy and intellectual disability (CR206 Oct 2017) Prescribing anti-epileptic drugs for people with epilepsy and intellectual disability (CR206 Oct 2017) This report addresses the extremely important area of epilepsy in the field of intellectual disability (ID), also known as learning disability. Epilepsy and ID are two conditions that carry stigma and can lead to social isolation. An individual who experiences both these problems faces huge challenges. This report aims

2018 Royal College of Psychiatrists

86. Diagnosis and management of epilepsy in adults

Diagnosis and management of epilepsy in adults SIGN 143 • Diagnosis and management of epilepsy in adults A national clinical guideline Evidence May 2015 · Revised 2018KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 - Meta-analyses, systematic reviews, or RCTs with a high risk of bias (...) in the web version of this document, which is the definitive version at all times. This version can be found on our web site www.sign.ac.uk. This document is produced from elemental chlorine-free material and is sourced from sustainable forests.Scottish Intercollegiate Guidelines Network Diagnosis and management of epilepsy in adults A national clinical guideline Revised 2018Scottish Intercollegiate Guidelines Network Gyle Square, 1 South Gyle Crescent Edinburgh EH12 9EB www.sign.ac.uk First published

2018 SIGN

87. Study suggests that pre-existing maternal epilepsy increases the risk of adverse perinatal outcomes

Study suggests that pre-existing maternal epilepsy increases the risk of adverse perinatal outcomes Study suggests that pre-existing maternal epilepsy increases the risk of adverse perinatal outcomes | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Study suggests that pre-existing maternal epilepsy increases the risk of adverse perinatal outcomes Article Text Commentary Women’s health & midwifery Study suggests that pre-existing maternal epilepsy

2018 Evidence-Based Nursing

88. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. (Full text)

Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Epilepsy is a common neurological condition with a worldwide prevalence of around 1%. Approximately 60% to 70% of people with epilepsy will achieve a longer-term remission from seizures, and most achieve that remission shortly after starting antiepileptic drug treatment. Most people with epilepsy are treated with a single antiepileptic drug (monotherapy) and current guidelines from the National (...) AEDs (carbamazepine, phenytoin, sodium valproate, phenobarbitone, oxcarbazepine, lamotrigine, gabapentin, topiramate, levetiracetam, zonisamide) currently used as monotherapy in children and adults with partial onset seizures (simple partial, complex partial or secondary generalised) or generalised tonic-clonic seizures with or without other generalised seizure types (absence, myoclonus).We searched the following databases: Cochrane Epilepsy's Specialised Register, CENTRAL, MEDLINE and SCOPUS

2017 Cochrane PubMed

89. Stiripentol (Diacomit) - for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome)

Stiripentol (Diacomit) - for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome) Final Appraisal Recommendation Advice No: 2617 – November 2017 Stiripentol (Diacomit ® ) 250 mg and 500 mg hard capsules; 250 mg and 500 mg powder for oral suspension in sachet Resubmission by Biocodex Additional note(s): • AWMSG considered that stiripentol (Diacomit ® (...) (where available) and the lay member perspective. This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Stiripentol (Diacomit ® ) is recommended for use within NHS Wales for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet syndrome) whose seizures are not adequately controlled

2017 All Wales Medicines Strategy Group

90. Psychological treatments for people with epilepsy. (Full text)

Psychological treatments for people with epilepsy. Given the significant impact epilepsy can have on the health-related quality of life (HRQoL) of individuals with epilepsy and their families, there is great clinical interest in evidence-based psychological treatments, aimed at enhancing psychological well-being in people with epilepsy. A review of the current evidence was needed to assess the effects of psychological treatments for people with epilepsy on HRQoL outcomes, in order to inform (...) future therapeutic recommendations and research designs.To assess the effects of psychological treatments for people with epilepsy on HRQoL outcomes.We searched the following databases on 20 September 2016, without language restrictions: Cochrane Epilepsy Group Specialized Register, CENTRAL, MEDLINE PsycINFO, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform (ICTRP). We screened the references from included studies and relevant reviews, and contacted researchers in the field

2017 Cochrane PubMed

91. Surgery for Drug-Resistant Epilepsy in Children. (PubMed)

Surgery for Drug-Resistant Epilepsy in Children. Neurosurgical treatment may improve seizures in children and adolescents with drug-resistant epilepsy, but additional data are needed from randomized trials.In this single-center trial, we randomly assigned 116 patients who were 18 years of age or younger with drug-resistant epilepsy to undergo brain surgery appropriate to the underlying cause of epilepsy along with appropriate medical therapy (surgery group, 57 patients) or to receive medical (...) ), and on the Vineland Social Maturity Scale (difference, 4.7; 95% CI, 0.4 to 9.1; P=0.03), but not on the Binet-Kamat intelligence quotient (difference, 2.5; 95% CI, -0.1 to 5.1; P=0.06). Serious adverse events occurred in 19 patients (33%) in the surgery group, including hemiparesis in 15 (26%).In this single-center trial, children and adolescents with drug-resistant epilepsy who had undergone epilepsy surgery had a significantly higher rate of freedom from seizures and better scores with respect to behavior

2017 NEJM

92. Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. (Full text)

Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. Detailed neuropathological information on the structural brain lesions underlying seizures is valuable for understanding drug-resistant focal epilepsy.We report the diagnoses made on the basis of resected brain specimens from 9523 patients who underwent epilepsy surgery for drug-resistant seizures in 36 centers from 12 European countries over 25 years. Histopathological diagnoses were determined through examination (...) of the specimens in local hospitals (41%) or at the German Neuropathology Reference Center for Epilepsy Surgery (59%).The onset of seizures occurred before 18 years of age in 75.9% of patients overall, and 72.5% of the patients underwent surgery as adults. The mean duration of epilepsy before surgical resection was 20.1 years among adults and 5.3 years among children. The temporal lobe was involved in 71.9% of operations. There were 36 histopathological diagnoses in seven major disease categories. The most

2017 NEJM PubMed

93. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. (Full text)

Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. This is an updated version of the Cochrane Review published in the Cochrane Library 2011, Issue 12.The majority of people with epilepsy have a good prognosis, but up to 30% of people continue to have seizures despite several regimens of antiepileptic drugs. In this review, we summarized the current evidence regarding eslicarbazepine acetate (ESL) when used as an add-on treatment for drug-resistant partial epilepsy.To evaluate (...) the efficacy and tolerability of ESL when used as an add-on treatment for people with drug-resistant partial epilepsy.The searches for the original review were run in November 2011. Subsequently, we searched the Cochrane Epilepsy Group Specialized Register (6 December 2016), the Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 11) and MEDLINE (1946 to 6 December 2016). There were no language restrictions. We reviewed the reference lists of retrieved studies to search for additional

2017 Cochrane PubMed

94. The role of high-frequency oscillations in epilepsy surgery planning. (Full text)

The role of high-frequency oscillations in epilepsy surgery planning. Epilepsy is a serious brain disorder characterized by recurrent unprovoked seizures. Approximately two-thirds of seizures can be controlled with antiepileptic medications (Kwan 2000). For some of the others, surgery can completely eliminate or significantly reduce the occurrence of disabling seizures. Localization of epileptogenic areas for resective surgery is far from perfect, and new tools are being investigated to more (...) accurately localize the epileptogenic zone (the zone of the brain where the seizures begin) and improve the likelihood of freedom from postsurgical seizures. Recordings of pathological high-frequency oscillations (HFOs) may be one such tool.To assess the ability of HFOs to improve the outcomes of epilepsy surgery by helping to identify more accurately the epileptogenic areas of the brain.For the latest update, we searched the Cochrane Epilepsy Group Specialized Register (25 July 2016), the Cochrane

2017 Cochrane PubMed

95. Yoga for epilepsy. (Full text)

Yoga for epilepsy. This is an updated version of the original Cochrane Review published in the Cochrane Library, Issue 5, 2015.Yoga may induce relaxation and stress reduction, and influence the electroencephalogram and the autonomic nervous system, thereby controlling seizures. Yoga would be an attractive therapeutic option for epilepsy if proved effective.To assess whether people with epilepsy treated with yoga:(a) have a greater probability of becoming seizure free;(b) have a significant (...) reduction in the frequency or duration of seizures, or both; and(c) have a better quality of life.For this update, we searched the Cochrane Epilepsy Group Specialized Register (3 January 2017), the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 12) in the Cochrane Library (searched 3 January 2017), MEDLINE (Ovid, 1946 to 3 January 2017), SCOPUS (1823 to 3 January 2017), ClinicalTrials.gov (searched 3 January 2017), the World Health Organization (WHO) International Clinical Trials

2017 Cochrane PubMed

96. Lacosamide - Epilepsy

Lacosamide - Epilepsy 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 20 July 2017 EMA/518597/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Lacosamide Accord International non-proprietary name (...) -onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy. The legal basis for this application refers to: Generic application (Article 10(1) of Directive No 2001/83/EC) The application submitted is composed of administrative information, complete quality data and literature from the reference medicinal product Vimpat instead of non-clinical and clinical unless justified otherwise. The chosen reference product is: Medicinal product which

2017 European Medicines Agency - EPARs

97. Are cannabinoids effective for epilepsy? (Full text)

Are cannabinoids effective for epilepsy? Several beneficial effects have been proposed for cannabinoids in different clinical conditions, including epilepsy. However, their clinical role is controversial. Searching in Epistemonikos database, which is maintained by screening multiple databases, we identified five systematic reviews including four randomized trials addressing the question of this article. We extracted data and generated a summary of findings following the GRADE approach. We (...) concluded it is not clear whether cannabinoids reduce the frequency of seizures in epilepsy because the certainty of the evidence is very low, and they probably increase adverse effects.

2017 Medwave PubMed

98. Epilepsy as a health problem among school children in Turaif, Northern Saudi Arabia, 2017 (Full text)

Epilepsy as a health problem among school children in Turaif, Northern Saudi Arabia, 2017 Epilepsy is the most common serious neurological disorder and is one of the world's most prevalent non-communicable diseases. There are no recently published data on the prevalence of epilepsy in school children in Northern Saudi Arabia.This study was conducted to determine the prevalence of epilepsy and to show some of its risk factors in school children and adolescents (6-18 years) in Turaif city (...) test and descriptive statistics.Out of 1,230 children, 66 (5.5%) had epilepsy; 68.2% of them were males and 31.8% females (p=0.000). Consanguinity between parents plays a significant role where 59.1% of cases had parents who were cousins (p=0.000). Family history also had a significant effect as 68.2% of cases had epilepsy cases in their families (p=0.000).Epilepsy prevalence among school children (6-18 years) in Turaif city is higher in males than females. Consanguinity and positive family history

2017 Electronic physician PubMed

99. Giant Epidermoid Cyst: A Rare Cause of Temporal Lobe Epilepsy (Full text)

Giant Epidermoid Cyst: A Rare Cause of Temporal Lobe Epilepsy Introduction  Epidermoid tumors represent approximately 0.3 to 1.8% of all intracranial brain tumors. Only 1.5% of all intracranial epidermoid cysts (ECs) invade the brain and secondary epilepsy is extremely rare. Since August 2014, a 59-year-old male smoker had been presenting bad smell feelings, totaling four episodes with sudden onset and duration of 2 minutes. On September 2014, after a sense of smell episode, it evolved (...) surgical strategy in individuals with ECs and seizures is not established. The evaluation of the cause and risk-benefit must be held to choose the appropriate surgical strategy: lesionectomy, lobectomy, or amygdalohippocampectomy. In this case, a lesionectomy was performed due to an absence of evidence of involvement of hippocampus and amygdala. Conclusion  Epilepsy secondary to ECs is a rare association. Lesionectomy can be an option with good results without increasing the morbidity.

2017 Journal of neurological surgery reports PubMed

100. Felbamate as an add-on therapy for refractory partial epilepsy. (Full text)

Felbamate as an add-on therapy for refractory partial epilepsy. This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (Issue 7, 2014) on 'Felbamate as an add-on therapy for refractory epilepsy'. Epilepsy is a chronic and disabling neurologic disorder, affecting approximately 1% of the population. Up to 30% of people with epilepsy have seizures that are resistant to currently available drugs. Felbamate is one of the second-generation (...) antiepileptic drugs and we have assessed its effects as an add-on therapy to standard drugs in this review.To evaluate the efficacy and tolerability of felbamate versus placebo when used as an add-on treatment for people with refractory partial-onset epilepsy.For the latest update we searched the Cochrane Epilepsy Specialized Register, CENTRAL, MEDLINE, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform, up to 20 October 2016. There were no language and time restrictions. We

2017 Cochrane PubMed